Meningococcal burden of disease in Argentina: 10 years epidemiologic review

Silvina Neyro1, Analia Urueña2, Adriana Efron3

  • 1Dirección de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, Buenos Aires, Argentina.

Insights

Invasive meningococcal disease (IMD) primarily affects infants, with incidence peaking in 2013 and declining thereafter. Vaccination programs are crucial for protecting against predominant serogroups like B and W.

Area of Science:

  • Epidemiology
  • Vaccinology
  • Public Health

Background:

  • Invasive meningococcal disease (IMD) is a severe, potentially fatal infection, disproportionately impacting infants.
  • Argentina implemented a national vaccination program targeting serogroups A, C, W, and Y (MenACWY) in 2017 for infants and adolescents.

Purpose of the Study:

  • To analyze the epidemiological burden of IMD in Argentina between 2010 and 2019.
  • To assess trends in IMD incidence, mortality, case-fatality rates, and serogroup distribution following the introduction of the MenACWY vaccine.

Main Methods:

  • Utilized national surveillance databases to collect and analyze IMD case data from 2010-2019.
  • Estimated incidence, mortality, case-fatality rates, and serogroup prevalence across different age groups.
  • Tracked changes in serogroup identification and distribution over the study period.

Main Results:

  • A total of 1,972 IMD cases were reported, with the highest incidence observed in infants under one year of age.
  • IMD incidence peaked in 2013 and subsequently declined; mortality was significantly higher in infants.
  • Serogroup B (48%) and W (42%) were most common, with a notable increase in serogroup B, particularly in infants, in recent years.

Conclusions:

  • IMD epidemiology is dynamic, with shifts in predominant serogroups observed.
  • Early-age vaccination is critical for protecting infants against prevalent and emerging serogroups.
  • Data supports evidence-based healthcare decision-making for IMD prevention and control.